ERBB2 and breast carcinoma: In HER2 (+) breast cancer, they have been registered for about a decade and include lapatinib [74](Tykerb; 2007), neratinib [75], pyrotinib [74] , and tucatinib [76] , while afatinib has not yet been registered for this indication.